dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Masanas Jimenez, Marc |
dc.contributor.author | Masia Fandos, Nuria |
dc.contributor.author | Suarez Cabrera, Leticia |
dc.contributor.author | Olivan Riera, Mireia |
dc.contributor.author | Soriano Fernández, Aroa |
dc.contributor.author | Majem Cavaller, Blanca |
dc.contributor.author | Jimenez Jimenez, Carlos Gonzalo |
dc.contributor.author | Boloix Amenós, Ariadna |
dc.contributor.author | Toledano Martin, Ignasi |
dc.contributor.author | Navarro Jimenez, Alexandra |
dc.contributor.author | Sánchez de Toledo Codina, Josep |
dc.contributor.author | Roma Castanyer, Josep |
dc.contributor.author | Moreno Martín-Retortillo, Lucas |
dc.contributor.author | Gallego Melcón, Soledad |
dc.contributor.author | Santamaria Margalef, Anna |
dc.contributor.author | Segura Ginard, Miguel |
dc.contributor.author | Guillén Burrieza, Gabriela |
dc.date.accessioned | 2022-05-06T12:52:33Z |
dc.date.available | 2022-05-06T12:52:33Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Masanas M, Masiá N, Suárez-Cabrera L, Olivan M, Soriano A, Majem B, et al. The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Clin Transl Med. 2021 Oct;11(10):e533. |
dc.identifier.issn | 2001-1326 |
dc.identifier.uri | https://hdl.handle.net/11351/7492 |
dc.description | KIF11 inhibitor; Targeted therapies; Metastasis |
dc.description.abstract | In summary, our study provides a rationale for the future
therapeutic integration in clinical trials of 4SC-205, an
structurally distinct oral KIF11 inhibitor that shows potent
antitumor activity in multiple preclinical neuroblastoma
models and sensitizes neuroblastoma cells to standard
chemotherapy and specific neuroblastoma-targeted therapies. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Clinical and Translational Medicine;11(10) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Medicació oral |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject | Neuroblastoma - Tractament |
dc.subject.mesh | Neuroblastoma |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | Administration, Oral |
dc.title | The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/ctm2.533 |
dc.subject.decs | neuroblastoma |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos |
dc.subject.decs | administración oral |
dc.relation.publishversion | https://doi.org/10.1002/ctm2.533 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Masanas M, Soriano A, Jiménez C, Boloix A, Roma J, Segura MF] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Masiá N, Suárez-Cabrera L, Majem B, Toledano I, Santamaria A] Laboratori de Cicle Cel•lular i Càncer, Grup de Recerca Biomèdica en Urologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Olivan M] Laboratori de Cicle Cel•lular i Càncer, Grup de Recerca Biomèdica en Urologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Translational Oncology Laboratory, Anatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona (UB), L’Hospitalet de Llobregat, Spain. [Guillén G] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Navarro A] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Sánchez de Toledo J] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Catalan Institute of Oncology (ICO), Barcelona, Spain. [Moreno L, Gallego S] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34709738 |
dc.identifier.wos | 000711947800022 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00530 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F02248 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/CPII18%2F00027 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |